{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024165","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.421625+00:00","generated_at":"2026-06-21T23:40:10.013479+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Monte Rosa Q3 net loss $27.3M; MRT-2359 Phase 1/2 dosing initiated","bullets":["Net loss of $27.3M in Q3 2022 vs $19.8M in Q3 2021; R&D expenses rose to $21.3M.","Cash, equivalents, and marketable securities $277.4M as of Sep 30, 2022; runway into late 2024.","Initiated patient dosing in Phase 1/2 trial for MRT-2359 (GSPT1 degrader) in MYC-driven solid tumors.","VAV1 molecular glue degrader program advanced into lead optimization for autoimmune diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024165","json":"https://secwatch.observer/filing/0000950170-22-024165.json","markdown":"https://secwatch.observer/filing/0000950170-22-024165.md","text":"https://secwatch.observer/filing/0000950170-22-024165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017022024165/0000950170-22-024165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017022024165/glue-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:40:10.013479+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}